Anastrozole
Anastrozole is a daily tablet that stops the body making oestrogen after the menopause. It treats and prevents hormone-receptor-positive breast cancer and is an alternative to tamoxifen after surgery for ductal carcinoma in situ.
Overview
Anastrozole is a non-steroidal aromatase inhibitor developed by Zeneca (now AstraZeneca). It is taken as a 1 mg tablet once a day and is only effective after the menopause, or in premenopausal women whose ovaries have been suppressed, because it does not stop ovarian oestrogen production.
The FDA approved it in 1995 for advanced breast cancer in postmenopausal women after tamoxifen and in 2002 for adjuvant treatment of early hormone-receptor-positive disease, after the ATAC trial showed fewer recurrences than tamoxifen. In prevention, IBIS-II halved the incidence of breast cancer in high-risk postmenopausal women. After breast-conserving surgery for ductal carcinoma in situ, NSABP B-35 and IBIS-II DCIS found it at least as effective as tamoxifen, with a different side-effect profile: joint pain, bone loss and fractures rather than hot flushes, clots and endometrial cancer. Letrozole and exemestane are the other aromatase inhibitors in the class; OnCo's letrozole page covers the class as a whole.
- Oestrogen receptor
- Ligand pocket blocked / receptor degraded
- Oestrogen kept out
Reversibly blocks aromatase (CYP19A1), the enzyme that makes oestrogen from androgens in fat, muscle and the tumour itself, cutting circulating oestrogen in postmenopausal women to near zero. Connects to Aromatase (CYP19A1).
1.Anastrozole acts on Aromatase (CYP19A1), the hormone receptor or the enzyme that makes the hormone.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1995 | Advanced breast cancer in postmenopausal women after tamoxifen |
| US | 2002 | Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Anastrozole" OR ABSTRACT:"Anastrozole" OR TITLE:"Arimidex" OR ABSTRACT:"Arimidex" OR TITLE:"ZD1033" OR ABSTRACT:"ZD1033") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Anastrozole, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCediranib
Shares AstraZeneca and the tag subtype-drugs-wave.
- TreatmentFormestane
Shares Aromatase (CYP19A1), Exemestane, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TreatmentAminoglutethimide
Shares Aromatase (CYP19A1), Exemestane, Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs).
- TechnologyAcupuncture for hot flushes on endocrine therapy
Shares Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs).
- TrialA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Shares Exemestane, Tamoxifen, AstraZeneca.
- PersonWendy Parulekar
Shares Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TechnologyAcupuncture for aromatase-inhibitor joint pain
Shares Exemestane, Letrozole (and other aromatase inhibitors), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- TrialSOFT & TEXT
Shares Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs).